Evaluation of Pharmacokinetic Interaction between PA-824

1 and Midazolam in Healthy Adult Subjects 2 3 4 5 Helen Winter 6 Erica Egizi 7 Ngozi Erondu 8 Ann Ginsberg 9 Doris J. Rouse 10 Diana Severynse-Stevens 11 Elliott Pauli 12 Daniel Everitt 13 14 15 16 17 1 School of Pharmacy, University of Otago, PO Box 56, Dunedin 9045, New Zealand 18 2 Global Alliance for TB Drug Development, 40 Wall Street, 24 Floor, New York, NY 19 10005, USA 20 3 RTI International, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA 21 22 23 24 25 26 27 Correspondent Footnote: 28

[1]  A. Diacon,et al.  14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial , 2012, The Lancet.

[2]  K. Dooley,et al.  TB and HIV Therapeutics: Pharmacology Research Priorities , 2012, AIDS research and treatment.

[3]  A. Diacon,et al.  Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824 , 2012, Antimicrobial Agents and Chemotherapy.

[4]  A. Diacon,et al.  Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients , 2010, Antimicrobial Agents and Chemotherapy.

[5]  M. Laurenzi,et al.  Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on Renal Function in Healthy Subjects , 2009, Antimicrobial Agents and Chemotherapy.

[6]  J. Chodakewitz,et al.  Effect of Different Durations of Ketoconazole Dosing on the Single‐Dose Pharmacokinetics of Midazolam: Shortening the Paradigm , 2009, Journal of clinical pharmacology.

[7]  P. Niyomrattanakit,et al.  PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.

[8]  J. Grosset,et al.  Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis , 2008, Antimicrobial Agents and Chemotherapy.

[9]  M. Matsumoto,et al.  OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.

[10]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.